BIOPHARMA
ByIs Regional Distribution Becoming a Strategic Lever for Big Pharma? Novartis Expands European Reach Through Malta Partnership
23 January 2026 Executive Summary Novartis Pharma Services AG has entered into a strategic distribution agreement with Vivian…
Can Localized Manufacturing Shield Big Pharma from Trade Volatility? Novartis Targets Zero U.S. Tariff Exposure by Mid-2026
23 January 2026 Executive Summary Novartis CEO Vas Narasimhan has outlined a decisive trade-risk mitigation strategy, stating that…
Is U.S. Manufacturing the Next Growth Hedge for Big Pharma? Novartis Commits $23 Billion to Domestic Expansion
23 January 2026 Executive Summary Novartis has unveiled a $23 billion investment plan to significantly expand its U.S.…
Can Ianalumab Anchor Novartis’ Next Growth Cycle as Patent Pressures Mount?
23 Jan 2026 Executive Summary Novartis has secured Breakthrough Therapy designation for ianalumab, a late-stage immunology asset, reinforcing…
Could Amgen’s 340B Pricing Practices Face Legal and Market Scrutiny?
23 January 2026 Executive Summary A healthcare advocacy group, Sagebrush, has filed a lawsuit against Amgen Inc., alleging…
Is Novo Nordisk Positioning Cell-Based Therapies as the Future of Diabetes Care?
23 January 2026 Executive Summary Novo Nordisk has expanded its strategic collaboration with Canadian biotech Aspect Biosystems, intensifying…
